Provided the relatively low incidence of the single gene mutations, clonal mutations (detected in >20% of tumor population) were grouped into the JAK/STAT (IL7R, JAK2, JAK1, CRLF2 mutations and CRLF2-rearrangements) and RAS/RTK (FLT3, KRAS, NRAS) pathways. This evidence concerns the gene JAK1 and neoplasm.